
CJC-1295 No DAC
10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.
Free U.S. shipping $175+

Sermorelin corresponds to the first 29 amino acids of growth-hormone-releasing hormone — the shortest fragment of the native sequence that retains receptor activity in laboratory assays.
Because it is the minimal active form, researchers use it as a baseline GHRH receptor agonist when characterizing receptor binding, signaling, or the effect of modifications made to longer or stabilized analogs.
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Analytical values reflect per-lot documentation and appear once a batch is released.
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
The 1-29 fragment of GHRH was identified as the minimal sequence retaining full receptor activity, forming the basis for sermorelin and downstream analogs.
Sermorelin has been used in decades of GHRH-pharmacology literature as a reference compound.

10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.

5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.

5 mg
GHRH analog with Drug Affinity Complex modification for extended-duration receptor research.

10 mg
Second-generation growth hormone releasing peptide studied as a ghrelin receptor agonist reference.